Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sigyn Therapy
  • Therapeutic Opportunities
    • Overview
    • Sepsis
    • Community Acquired Pneumonia
    • Emerging Pandemic Threats
    • ESRD Inflammation and Endotoxemia
  • News
    • Press Releases
    • Presentations
    • Resources
  • Media
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Email Alerts
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • CEO Notes

Press Releases

News

News

  • Press Releases
  • Presentations
  • Resources
Jul 15, 2021 7:30am EDT

Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma

Jul 13, 2021 9:31am EDT

Sigyn Therapeutics Reports Preliminary Results of Hepatic Encephalopathy Toxin Study

Jun 28, 2021 9:30am EDT

The Evolution of Blood Purification Technologies to Treat Emerging Pandemic Threats, Including COVID-19

Apr 21, 2021 4:15pm EDT

Sigyn Therapeutics™ Discloses In-Vitro Viral Pathogen Study

Mar 08, 2021 3:08pm EST

Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 04, 2021 8:10am EST

Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.

Jan 26, 2021 8:30am EST

Sigyn Therapeutics Appoints Eric Lynam as Head of Clinical Affairs

Jan 12, 2021 8:30am EST

Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies

Jan 06, 2021 8:30am EST

Sigyn Therapeutics™ Reports Results of Pilot Study to Address Inflammatory CytoVesicles

Dec 01, 2020 8:45am EST

Sigyn Therapeutics™ Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines From Human Blood Plasma

  • Previous
  • 1
  • 2
  • 3
  • 4
  • Next
RSS
© 2023 Sigyn Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap